Eli Lilly cut prices 13% and grew 48%

Revenue up 48%, realised prices down 13%, and a $27 billion factory bet. India is where this model gets tested first.

Five years ago, owning a big pharma company meant owning a patent and the pricing power that came with it. Not anymore. Lilly's realised prices fell 13% last quarter and revenue still rose 48% to $23.0 billion, because volume went up 60%, per the company's Q2 2026 release. The moat has quietly moved from the molecule to the factory, and most models still have not caught up. That's why we built Winvesta Crisps, to decode what's actually driving the companies you own, in plain language, before the consensus catches up. 60,000+ investors from all over India are already in. What about you?

🔔 Add winvestacrisps@substack.com to your email list so our updates never land in spam.

Most investors still hold Eli Lilly in their heads as a high-margin patent business: one blockbuster molecule, one protected price, one fat margin. The Q2 2026 print says something else. Revenue reached $23.0 billion, up 48% on the year, and the way it got there was a 60% jump in volume against a 13% fall in realised prices, per Lilly's earnings release. Outside the US the split is starker still: international revenue rose 80%, built on a 113% volume increase and a 36% price decline. Lilly is deliberately trading price for reach, and it is doing so while carrying a market value of roughly $1.06 trillion, per companiesmarketcap data. The stock, meanwhile, is up about 8.9% this year against the S&P 500's 12.8%. A company compounding revenue at 48% is lagging the index. That gap is the story.

---

🧩 What Lilly actually sells now

Two products do most of the work. Mounjaro, the tirzepatide injection sold for type 2 diabetes, brought in $9.9 billion in the quarter, up 91%. Zepbound, the same molecule branded for weight management, added $4.9 billion, up 46%. Together that is roughly $14.8 billion, close to two-thirds of everything Lilly sold in the three months, per the company's product tables.

That concentration is the first thing to sit with. This is a 150-year-old company whose quarter is now decided by one peptide sold under two names.

The second thing is newer and matters more for the next five years. Foundayo, Lilly's once-daily oral GLP-1 (orforglipron), was approved by the FDA on 1 April 2026 and started shipping through LillyDirect on 6 April, per AJMC. It booked $98 million in its first partial quarter. On the earnings call management said roughly one in four new patient starts are now on Foundayo, and the prescriber base went from about 8,000 to about 36,000 in a single quarter.

A pill changes the physics of this market. Injectables need cold chain, pen devices and a patient willing to inject weekly. Orforglipron is a small molecule, which means it can be made in conventional chemical plants rather than the far scarcer peptide and sterile-fill capacity, and it carries no fasting requirement before meals, unlike oral semaglutide. For countries where the cold chain thins out fifty kilometres from a metro, that difference is the whole market.

The rest of the portfolio has stopped being a rounding error, which is easy to miss. Lilly said oncology, immunology and neuroscience together grew 121% in the quarter, helped by newer launches. Ebglyss reached $201 million, up 131%. Jaypirca hit $192 million, up 56%. Omvoh reached $102 million, up 36%. None of these will move a $23 billion quarter on their own. Collectively they are the answer to the fair question of what Lilly is when tirzepatide's exclusivity eventually runs out.

---

⚙️ The growth engine: volume, not price

Here is the mechanism, and it is genuinely unusual for pharma.

Lilly is cutting prices on purpose, in three directions at once, and letting volume do the compounding.

In the US, the company agreed in November 2025 to most favoured nation pricing terms with the Trump administration, per CNBC. Existing GLP-1s go to the government at around $245 a month across non-starting doses. Starting doses of the obesity pills were set at $149 a month. Certain Medicare patients pay a $50 monthly copay, and Medicare began covering obesity drugs for some patients from mid-2026, the first time that has happened. The administration's TrumpRx.gov direct-to-consumer site launched in January 2026.

On the call, management put US obesity pricing down 9% excluding rebates. Against that, they described late July as an inflection point, with monthly Foundayo volumes close to doubling once Medicare bridge access went live. Lower price, wider door, more patients.

Internationally the trade is far more aggressive: a 36% fall in realised price bought a 113% rise in volume. That is not a discount, it is a different business model. Lilly told investors its international incretin share is running at roughly 55%.